ライフサイエンスコーパス: modafinil

1 apses in brain slices from mice treated with modafinil.

2 ic wake-promoting action of amphetamines and modafinil.

3 mprovements in response inhibition following modafinil.

4 rotonin and norepinephrine transporters than modafinil.

5 We also examined modafinil (0.075 to 75 mg/kg) on Pavlovian fear conditio

6 A low dose of pretraining modafinil (0.75 mg/kg) enhanced memory of contextual fea

7 2-[(Diphenylmethyl)sulfinyl]acetamide (modafinil, (+/-)-1) is a unique dopamine uptake inhibito

8 ast 4 weeks, were randomly assigned to daily modafinil (100 mg on days 1 to 14; 200 mg on days 15 to

9 %; placebo, 11%; p = 0.044) and nervousness (modafinil, 12%; placebo, 3%; p = 0.024) were the most co

10 received either lactose placebo (n = 19) or modafinil 200 mg (n = 20) after 1 night of sleep depriva

11 tested the effects of adjunctive single-dose modafinil 200 mg on rule-related 4-30 Hz oscillations in

12 task to examine effects of a single dose of modafinil (200 mg) on response inhibition and underlying

13 Headache (modafinil, 23%; placebo, 11%; p = 0.044) and nervousness

14 rticipants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every mornin

15 from baseline to day 28 (mean score change: modafinil, 5.29; 95% CI, 2.57 to 8.02; placebo, 5.09; 95

16 th score < 10) was significantly higher with modafinil (51%) than with placebo (27%) (p < 0.01), but

17 A high dose of modafinil (75 mg/kg ip) given before training improved a

18 Modafinil, a wake-promoting drug used to treat narcoleps

19 To determine potential pathways via which modafinil acts, we administered a range of doses of moda

20 Within the AD group modafinil administration improved response inhibition (r

21 Modafinil administration was associated with significant

22 Moreover, caffeine and modafinil affected wakefulness-induced changes in functi

23 Modafinil also decreased [(11)C]cocaine binding potentia

24 Patients who were receiving modafinil also had a reduction in the frequency and dura

25 This low dose of modafinil also increased the number of Fos-immunoreactiv

26 Moreover, modafinil, an anti-narcoleptic drug with ill-defined mec

27 A series of modafinil analogues have been reported so far, but more

28 Herein, we report a series of modafinil analogues that have an atypical DAT inhibitor

29 the wake-promoting antinarcoleptic compounds modafinil and amphetamine increase extracellular dopamin

30 (+/-)-Modafinil and its R-(-)- and S-(+)-enantiomers were synt

31 ole increased PPI in low PPI gaters, whereas modafinil and lorazepam attenuated PPI in both groups.

32 The CNS stimulants modafinil and methylphenidate are recommended for the tr

33 (n=28), amisulpride and lorazepam (n=30), or modafinil and valproate (n=30), and placebo.

34 Rasagiline, modafinil, and doxepin are associated with improvement i

35 ivity to caffeine, reduced-responsiveness to modafinil, and increased homeostatic response to prolong

36 Lorazepam, modafinil, and valproate did not influence P50 suppressi

37 rtness-promoting medications armodafinil and modafinil are associated with improved alertness during

38 However, these drugs and others, including modafinil, are being increasingly used by healthy people

39 study aims to further examine the effects of modafinil as a cognitive enhancer on hippocampus-depende

40 Future trials with R-modafinil as a substitute therapy with the potential ben

41 a neurobiological rationale for implementing modafinil as an adjunct in the treatment of alcohol depe

42 Treatment with modafinil, as compared with placebo, resulted in a modes

43 These data suggest that adjunctive modafinil at doses of 100-200 mg a day may improve depre

44 These findings demonstrate that modafinil at least partly exerts its effects by targetin

45 ith spontaneous wakefulness, we administered modafinil at midnight, during the normal waking period o

46 ian phase or ambient light, we also injected modafinil at noon on a normal light/dark cycle or in con

47 (+/-)-, R-, and S-modafinil bind to the DAT and inhibit DA uptake less pot

48 In this pilot study, modafinil blocked dopamine transporters and increased do

49 These findings indicate that modafinil can improve response inhibition in alcohol-dep

50 espite these benefits, patients treated with modafinil continued to have excessive sleepiness and imp

51 Modafinil decreased mean (SD) [(11)C]raclopride binding

52 Compared with placebo, modafinil decreased nighttime sleep latency and increase

53 Modafinil did not adversely affect daytime sleep as comp

54 Pretraining modafinil did not affect cued conditioning at any dose t

55 When given only before testing, modafinil did not affect water maze performance.

56 Modafinil did not improve cognitive control in all schiz

57 In contrast to previous studies, modafinil did not produce statistically significant incr

58 R-modafinil displays an in vitro profile different from co

59 The pharmacologic agent modafinil enhances cognitive control functions in both h

60 up study assessed the efficacy and safety of modafinil for the treatment of residual daytime sleepine

61 We evaluated the use of modafinil for treating sleepiness in patients with this

62 plasticity in these neurons, suggesting that modafinil functions through activation of the dopamine s

63 ssion rates were significantly higher in the modafinil group (44% and 39%) compared with the placebo

64 n IDS score was significantly greater in the modafinil group (mean dose, 177 mg/day) compared with th

65 The modafinil group (n=14), relative to placebo group (n=13)

66 ments for the secondary outcomes; 47% of the modafinil group and 23% of the placebo group stated that

67 gent hypomania or mania (six patients in the modafinil group and five in the placebo group) or hospit

68 ve symptoms was significantly greater in the modafinil group by week 2, and this greater improvement

69 gher cognitive function; participants in the modafinil group worked more efficiently when solving wor

70 Modafinil had no effect on cancer-related fatigue and sh

71 any dose tested, and immediate posttraining modafinil had no effect on either cued or contextual fea

72 Modafinil has been shown to promote wakefulness and some

73 (+/-)-Modafinil has piqued interest as a treatment for attenti

74 lar to that found in the wake-promoting drug modafinil have been synthesized.

75 DA uptake less potently than cocaine, with R-modafinil having approximately threefold higher affinity

76 tive at reducing daytime somnolence (such as modafinil) hold potential for the treatment of fatigue i

77 Some piperidine-based nocaine/modafinil hybrid ligands have been designed, synthesized

78 Modafinil improved performance on tests of higher cognit

79 into account when considering treatment with modafinil in AD.

80 aluate the efficacy and safety of adjunctive modafinil in bipolar depression, which is often characte

81 articipants revealed a normalizing effect of modafinil in cocaine-dependent participants.

82 Focal response to modafinil in the left dorsolateral prefrontal cortex and

83 to evaluate the efficacy and tolerability of modafinil in the management of fatigue in patients with

84 ess for potential abuse of and dependence on modafinil in vulnerable populations.

85 We found that 75 mg/kg modafinil increased Fos immunoreactivity in the tuberoma

86 ault mode network, which was associated with modafinil-induced improvement in cognitive control in al

87 ients with initial poor response inhibition, modafinil-induced SSRT improvement was accompanied by gr

88 hip between baseline response inhibition and modafinil-induced SSRT improvement was mediated by these

89 To contrast modafinil-induced wakefulness with spontaneous wakefulne

90 The effect of modafinil interacted with the abstinence week and was as

91 Modafinil is a wake promoting compound with high potenti

92 Modafinil is an increasingly popular wake-promoting drug

93 Modafinil is approved by the U.S. Food and Drug Administ

94 Modafinil is now considered the first-line treatment for

95 e some evidence of benefits for galantamine, modafinil, levodopa, rotigotine, clozapine, duloxetine,

96 Modafinil may be a useful adjunct treatment for the mana

97 These observations suggest that modafinil may promote waking via activation of TMN and o

98 the normally robust wake-promoting action of modafinil, methamphetamine, and the selective DAT blocke

99 The R-enantiomer of modafinil might have unique pharmacological properties t

100 ffects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a randomized double-blind, pl

101 (+/-)-Modafinil (MOD) is used clinically for the treatment of

102 (+/-)Modafinil ((+/-)MOD) and its R-enantiomer (R-modafinil;

103 Patients received modafinil (n = 77) (200 mg/d, Week 1; 400 mg/d, Weeks 2

104 were randomly assigned to receive adjunctive modafinil (N=41) or placebo (N=44) for 6 weeks.

105 ts were randomly assigned, and 160 patients (modafinil, n = 75; placebo, n = 85) completed questionna

106 otentially explaining an increased effect of modafinil observed in MCHR1 KO mice.

107 ioligand) was used to measure the effects of modafinil on extracellular dopamine and on dopamine tran

108 tudy was to investigate the acute effects of modafinil on prefrontal activation and cognitive control

109 was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic coc

110 tigate the effects of the cognitive enhancer modafinil on within-network and between-network resting-

111 k sleep disorder to receive either 200 mg of modafinil or placebo before the start of each shift.

112 Subjects received 300 mg/day modafinil or placebo during sleep restriction.

113 phrenia were studied twice, receiving either modafinil or placebo prior to functional magnetic resona

114 During modafinil or placebo treatment, the mean duration of nCP

115 ysis studies demonstrated that both R- and S-modafinil produced increases in extracellular DA concent

116 pathological gambling, N-acetyl cysteine and modafinil, produced significant improvement for patholog

117 Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep arc

118 Modafinil (Provigil, Modiodal), an antinarcoleptic and m

119 is to study the pharmacological actions of R-modafinil (R-MOD) and S-modafinil (S-MOD) on nicotine-ta

120 Modafinil ((+/-)MOD) and its R-enantiomer (R-modafinil; R-MOD) have been investigated for their poten

121 Treatment with 200 mg of modafinil reduced the extreme sleepiness that we observe

122 Modafinil (relative to placebo) enhanced oscillatory pow

123 a-glycyrrhetinic derivatives or mefloquine), modafinil restored electrotonic coupling within 30 min.

124 logical actions of R-modafinil (R-MOD) and S-modafinil (S-MOD) on nicotine-taking and nicotine-seekin

125 stimulants, although the exact mechanisms of modafinil's actions in wakefulness and cognitive enhance

126 These results suggest that modafinil's effects of memory are more selective than am

127 Modafinil significantly improved daytime sleepiness, wit

128 Modafinil significantly increased the negative coupling

129 arch on alerting agents such as caffeine and modafinil that interact with the dopaminergic pathway an

130 sitivity and assesses the effects of a drug, modafinil, that increases alertness during wakefulness.

131 abuse, and considering the increasing use of modafinil, these results highlight the need for heighten

132 the initial efficacy findings for baclofen, modafinil, tiagabine, and topiramate.

133 controlled clinical trials, namely baclofen, modafinil, tiagabine, and topiramate.

134 We used the pharmacological agent modafinil to promote low-tonic/high-phasic LC-NE activit

135 il acts, we administered a range of doses of modafinil to rats, recorded sleep/wake activity, and stu

136 mice, Alprazolam (to put them to sleep) and Modafinil (to wake them up).

137 in vehicle-treated cage-mates of Alprazolam/Modafinil-treated mice, suggesting that behavioral inter

138 Modafinil treatment in schizophrenia augments middle-fre

139 nic prolonged wakefulness in mice induced by modafinil treatment produced long-term potentiation (LTP

140 These outcomes were not affected by modafinil treatment.

141 Caffeine and modafinil, two wake-promoting agents that have no analge

142 utant compared with wild-type DAT, whereas S-modafinil was affected less.

143 Modafinil was associated with increased daytime sleep la

144 R-modafinil was significantly less potent in the DAT Y156F

145 R- and S-modafinil were also evaluated in microdialysis studies i

146 sured by changes in binding potential) after modafinil when compared with after placebo.